Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers
Howard E. Gendelman, MD, is chairman of the Department of Pharmacology and Experimental Neuroscience at the University of Nebraska Medical Center. He is credited in unraveling how functional alterations in brain immunity induce metabolic changes and ultimately lead to neural cell damage for a broad range of infectious, metabolic and neurodegenerative disorders. These discoveries have had broad implications in developmental therapeutics aimed at preventing, slowing or reversing neural maladies. This work has led to novel immunotherapy and nanomedicine strategies for Parkinson’s and viral diseases being tested in early clinical trials. Dr. Gendelman obtained a bachelor’s degree in natural sciences and Russian studies with honors from Muhlenberg College and his MD from the Pennsylvania State University-Hershey Medical Center, where he was the 1999 Distinguished Alumnus. He completed a residency in internal medicine at Albert Einstein College of Medicine and a fellowship in neurology and medicine at Johns Hopkins Medical Center.
Dr. Gendelman’ research focuses on the role played by glial inflammatory activities in brain disease. The work bridges immunology, neuroscience and pharmacology and crosses disease barriers for studies of HIV-1-associated neurocognitive disorders, Parkinson’s disease (PD) and amyotrophic lateral sclerosis (ALS). The major goal is to use immune-based approaches to reverse nerve cell damage.
Yuling Zhao, Matthew J. Haney, Vivek Mahajan, Benjamin C. Reiner, Anna Dunaevsky, R. Lee Mosley, Alexander V. Kabanov, Howard E. Gendelman and Elena V. Batrakova
Research Article: J Nanomed Nanotechnol 2011, S4-003